Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials

Background Chronic spontaneous urticaria (CSU) is defined by itchy hives, angioedema, or both for at least 6 weeks. Omalizumab, an anti-IgE antibody that affects mast cell and basophil function, is a promising new treatment option. As of now, however, the efficacy and safety of different doses of om...

Ausführliche Beschreibung